BLINCYTO®

(Blinatumomab)

Documentation

Patented
Approved 2014
FDA Letter
FDA Label
Full Sequence

Brief Summary

Function Type: TDCC
Target: CD19 CD3
Indication Category: Cancer

Approved Indications

Detailed Summary

Side Effects

References

Wikipedia
Drugs.com
FDA